When is ajovy patent expiry loe usa?

Patent Expiration Timeline: Ajovy in the US

Ajovy, a migraine preventive treatment developed by Teva Pharmaceuticals, received FDA approval in 2018 for the acute treatment of migraine, including the use for the prevention of migraines.

The patent for Ajovy's active ingredient, fremanezumab, expires in 2035 in the United States [1]. However, the actual market exclusivity for the drug has been impacted by various factors, including:

* Orphan Drug Exclusivity: Ajovy received orphan drug designation for the treatment of cluster headache, granting an additional 7-year market exclusivity from the date of FDA approval in this indication [2].
* Exclusivity under Hatch-Waxman: Fremanezumab, the active ingredient in Ajovy, has a patent that would grant Teva exclusivity until 2035, assuming no generic or biosimilar competition prior to then [1].

Generic and Biosimilar Competition: Impact on Patent Expiration

As of the last update, there are no approved generics or biosimilars available for Ajovy in the US market. However, it's essential to monitor patent litigation, settlements, and competition from generics and biosimilars, which can impact the final patent expiration date.

Impact on Pricing and Accessibility

The expiration of Ajovy's patent is expected to lead to increased competition, potentially lowering prices and improving accessibility for patients. However, the actual impact will depend on various factors, including the emergence of generics and biosimilars, as well as market dynamics.

Sources:

[1] DrugPatentWatch.com: Fremanezumab patents in the United States (https://www.drugpatentwatch.com/US/Patents/Freenza/Fremanezumab-Patents)

[2] FDA: Orphan Drug Designation (https://www.fda.gov/drugs/development-approval-process-drugs/other-designations/orphan-drug-designation)

Note: This information is subject to change as patent laws and market developments evolve.